Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Mersana Therapeutics Stock Is Soaring Today

By Cory Renauer – Updated Apr 8, 2020 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company raised more money to keep developing potential new cancer therapies.

What happened

Shares of Mersana Therapeutics (MRSN 7.05%), a clinical-stage biotechnology company, are surging today after it raised more capital than expected in a secondary share offering. Seeing the company raise $65 million to develop novel cancer therapies pushed the stock 20.2% higher as of 2:18 p.m. EDT on Wednesday.

So what 

On March 31, Mersana released phase 1 results for the most advanced candidate in the company's development pipeline, XMT-1536. Investors reacting to the underwhelming data pushed the stock lower.

Person in a suit looking up at an upward sloping chart.

Image source: Getty Images.

Lackluster data probably should have made raising a significant sum in an at-the-market offering impossible, but the company still managed to sell 10.9 million shares at $5.59 and another 2 million shares at $7.74 on Tuesday. Altogether, the company raised $65 million before fees in an offering that pushed its outstanding share count about 30% higher.

Now what

Mersana will use the proceeds of its latest offering to advance its pipeline of therapies that aim for an unproven target, NaPi2b, a protein often found in cancer cells. At the moment XMT-1536 is the only new drug candidate the company has in clinical-stage testing.

During the phase 1 trial that disappointed in March, Mersana treated 59 patients with ascending doses of XMT-1536, and none achieved complete remission. Investigators reported tumor shrinkage for just five patients, and only three still have tumors smaller than when they began taking the experimental therapy.

Mersana finds the results of the ascending-dose phase encouraging enough to continue treating patients with lung and ovarian cancer using the highest tolerable dosage in an extension study. In the second half of the year, the company also expects to begin a proof-of-concept study with XMT-1592, another antibody that aims for NaPl2b usually found on cancer cells but uses a different chemotherapy agent to kill those cells. Given the results we've seen so far, the chances of Mersana's candidates showing a significant survival benefit in a larger, more-expensive trial seem very slim.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mersana Therapeutics, Inc. Stock Quote
Mersana Therapeutics, Inc.
$7.59 (7.05%) $0.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.